1. Harley HG, Rundle SA, Reardon W, Myring J, Crow S, Brook JD, et al. Unstable DNA sequence in myotonic dystrophy. Lancet. 1992. 339:1125–1128.
2. Meola G, Moxley RT III. Schapira AHV, Griggs RC, editors. Myotonic disorder: Myotonic dystrophy and proximal myotonic myopathy. Muscle diseases. 1999. Woburn: Butterworth-Heinemann;115–134.
3. Caccia MR, Negri S, Parvis VP. Myotonic dystrophy with neural involvement. J Neurol Sci. 1972. 16:253–269.
4. McComas AJ, Sica RE, Toyonaga K. Incidence, severity, and time-course of motoneurone dysfunction in myotonic dystrophy: their significance for an understanding of anticipation. J Neurol Neurosurg Psychiatry. 1978. 41:882–893.
5. Jamal GA, Weir AI, Hansen S, Ballantyne JP. Myotonic dystrophy. A reassessment by conventional and more recently introduced neurophysiological techniques. Brain. 1986. 109:1279–1296.
6. Olson ND, Jou MF, Quast JE, Nuttall FQ. Peripheral neuropathy in myotonic dystrophy. Relation to glucose intolerance. Arch Neurol. 1978. 35:741–745.
7. Paramesh K, Smith BH, Kalyanaraman K. Early onset myotonic dystrophy in association with polyneuropathy. J Neurol Neurosurg Psychiatry. 1975. 38:1136–1139.
8. Perseghin G, Caumo A, Arcelloni C, Benedini S, Lanzi R, Pagliato E, et al. Contribution of abnormal insulin secretion and insulin resistance to the pathogenesis of type 2 diabetes in myotonic dystrophy. Diabetes Care. 2003. 26:2112–2118.
9. Logullo F, Censori B, Danni M, Del Pesce M, Di Bella P, Provinciali L. Peripheral neuropathy in myotonic dystrophy: electrophysiological and clinical features. Electromyogr Clin Neurophysiol. 1992. 32:515–520.
10. Roohi F, List T, Lovelace RE. Slow motor nerve conduction in myotonic dystrophy. Electromyogr Clin Neurophysiol. 1981. 21:97–105.
11. Bril V. NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol. 1999. 41:Suppl 1. 8–13.
12. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994. 17:1281–1289.
13. Mogyoros I, Kiernan MC, Burke D. Strength-duration properties of human peripheral nerve. Brain. 1996. 119:439–447.
14. Z'Graggen WJ, Lin CS, Howard RS, Beale RJ, Bostock H. Nerve excitability changes in critical illness polyneuropathy. Brain. 2006. 129:2461–2470.
15. Dyck PJ. Arnold Gries F, Cameron NE, Low PA, Ziegler D, editors. Severity and staging of diabetic polyneuropathy. Textbook of diabetic neuropathy. 2003. NewYork: Georg Thieme Verlag;170–175.
16. Krishnan AV, Kiernan MC. Axonal function and activity-dependent excitability changes in myotonic dystrophy. Muscle Nerve. 2006. 33:627–636.
17. Cros D, Harnden P, Pouget J, Pellissier JF, Gastaut JL, Serratrice G. Peripheral neuropathy in myotonic dystrophy: a nerve biopsy study. Ann Neurol. 1988. 23:470–476.
18. De Freitas GR, De Freitas MR, Nascimento OJ. [Sural nerve biopsy in myotonic muscular dystrophy]. Arq Neuropsiquiatr. 1996. 54:19–24.
19. Mondelli M, Rossi A, Malandrini A, Della Porta P, Guzaai GC. Axonal motor and sensory neuropathy in myotonic dystrophy. Acta Neurol Scand. 1993. 88:141–148.
20. Pfeilsticker BH, Bertuzzo CS, Nucci A. Electrophysiological evaluation in myotonic dystrophy: correlation with CTG length expansion. Arq Neuropsiquiatr. 2001. 59:186–191.
21. Kuwabara S, Misawa S. Axonal ionic pathophysiology in human peripheral neuropathy and motor neuron disease. Curr Neurovasc Res. 2004. 1:373–379.
22. Misawa S, Kuwabara S, Kanai K, Tamura N, Hiraga A, Nakata M, et al. Axonal potassium conductance and glycemic control in human diabetic nerves. Clin Neurophysiol. 2005. 116:1181–1187.
23. Misawa S, Kuwabara S, Ogawara K, Kitano Y, Hattori T. Strength-duration properties and glycemic control in human diabetic motor nerves. Clin Neurophysiol. 2005. 116:254–258.
24. Misawa S, Kuwabara S, Ogawara K, Kitano Y, Yagui K, Hattori T. Hyperglycemia alters refractory periods in human diabetic neuropathy. Clin Neurophysiol. 2004. 115:2525–2529.